Related Experiment Video
Updated: Mar 7, 2026
Bacterial Delivery of RNAi Effectors: Transkingdom RNAi
Published on: August 18, 2010
CK2 Molecular Targeting-Tumor Cell-Specific Delivery of RNAi in Various Models of Cancer
Janeen H Trembley1,2,3, Betsy T Kren4,5,6, Md Joynal Abedin7,8
1Research Service, Minneapolis VA Health Care System, Minneapolis, MN 55417, USA. trem0005@umn.edu.
Abstract:
Protein kinase CK2 demonstrates increased protein expression relative to non-transformed cells in the majority of cancers that have been examined. The elevated levels of CK2 are involved in promoting not only continued proliferation of cancer cells but also their resistance to cell death; thus, CK2 has emerged as a plausible target for cancer therapy. Our focus has been to target CK2 catalytic subunits at the molecular level using RNA interference (RNAi) strategies to achieve their downregulation. The delivery of oligonucleotide therapeutic agents warrants that they are protected and are delivered specifically to cancer cells. The latter is particularly important since CK2 is a ubiquitous signal that is essential for survival. To achieve these goals, we have developed a nanocapsule that has the properties of delivering an anti-CK2 RNAi therapeutic cargo, in a protected manner, specifically to cancer cells. Tenfibgen (TBG) is used as the ligand to target tenascin-C receptors, which are elevated in cancer cells. This strategy is effective for inhibiting growth and inducing death in several types of xenograft tumors, and the nanocapsule elicits no safety concerns in animals. Further investigation of this therapeutic approach for its translation is warranted.
Insights
This study developed a targeted nanocapsule to deliver RNA interference (RNAi) to cancer cells, effectively downregulating protein kinase CK2 (CK2) and inhibiting tumor growth without safety concerns.
Area of Science:
- Oncology
- Biotechnology
- Molecular Biology
Background:
- Protein kinase CK2 (CK2) is overexpressed in many cancers, promoting cell proliferation and survival.
- CK2's essential role in normal cells makes targeted delivery of therapeutics crucial.
- RNA interference (RNAi) offers a strategy to downregulate CK2 catalytic subunits.
Purpose of the Study:
- To develop a nanocapsule for targeted delivery of anti-CK2 RNAi therapeutics.
- To ensure protection and specific delivery of therapeutic cargo to cancer cells.
- To evaluate the efficacy and safety of this nanocapsule-based cancer therapy.
Main Methods:
- Development of a nanocapsule system for RNAi delivery.
- Incorporation of Tenfibgen (TBG) ligand for targeting tenascin-C receptors on cancer cells.
- In vivo testing in xenograft tumor models.
Main Results:
- The nanocapsule successfully delivered anti-CK2 RNAi cargo specifically to cancer cells.
- The strategy demonstrated significant inhibition of tumor growth and induction of cancer cell death.
- The nanocapsule formulation showed no observable safety concerns in animal models.
Conclusions:
- Targeted nanocapsule delivery of anti-CK2 RNAi is a promising strategy for cancer therapy.
- This approach offers specific targeting and avoids toxicity associated with CK2 inhibition.
- Further investigation is warranted for clinical translation of this therapeutic system.
Related Concept Videos
02:15Experimental RNAi
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:34Inhibition of Cdk Activity
01:23RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...